Millennium Management LLC raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 136.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 478,244 shares of the biopharmaceutical company’s stock after purchasing an additional 276,154 shares during the quarter. Millennium Management LLC owned about 0.45% of Regeneron Pharmaceuticals worth $179,801,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the business. Harding Loevner LP raised its position in Regeneron Pharmaceuticals by 589.2% in the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the period. Polen Capital Management LLC raised its position in Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after purchasing an additional 15,931 shares during the period. Geode Capital Management LLC raised its position in Regeneron Pharmaceuticals by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock valued at $330,385,000 after purchasing an additional 30,581 shares during the period. Franklin Resources Inc. increased its position in shares of Regeneron Pharmaceuticals by 4.5% during the fourth quarter. Franklin Resources Inc. now owns 819,796 shares of the biopharmaceutical company’s stock worth $308,212,000 after acquiring an additional 35,123 shares during the last quarter. Finally, Clearbridge Investments LLC increased its position in shares of Regeneron Pharmaceuticals by 6.2% during the fourth quarter. Clearbridge Investments LLC now owns 806,762 shares of the biopharmaceutical company’s stock worth $303,310,000 after acquiring an additional 47,010 shares during the last quarter. 66.40% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $334.00 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 52 week low of $313.53 and a 52 week high of $543.55. The company has a market capitalization of $37,106.66, a P/E ratio of 32.73, a price-to-earnings-growth ratio of 1.08 and a beta of 1.54.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.80% of the company’s stock.
A number of analysts have recently issued reports on the company. Jefferies Group reaffirmed a “hold” rating and set a $421.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, February 2nd. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an “equal weight” rating in a research report on Friday, February 9th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Finally, Guggenheim set a $530.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $449.49.
ILLEGAL ACTIVITY NOTICE: “Millennium Management LLC Raises Position in Regeneron Pharmaceuticals Inc (REGN)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/14/millennium-management-llc-raises-position-in-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.